Nick Finer
About
In The Last Decade
Nick Finer
186 papers receiving 9.4k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Physiology 3.8k
- Pharmacology 3.2k
- Endocrinology, Diabetes and Metabolism 3.1k
- Surgery 2.5k
- Public Health, Environmental and Occupational Health 1.5k
Countries citing papers authored by Nick Finer
This map shows the geographic impact of Nick Finer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nick Finer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nick Finer more than expected).
Fields of papers citing papers by Nick Finer
This network shows the impact of papers produced by Nick Finer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nick Finer. The network helps show where Nick Finer may publish in the future.
Co-authorship network of co-authors of Nick Finer
This figure shows the co-authorship network connecting the top 25 collaborators of Nick Finer. A scholar is included among the top collaborators of Nick Finer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nick Finer. Nick Finer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 55 | |
| 2 | 43 | |
| 3 | 27 | |
| 4 | 80 | |
| 5 | 21 | |
| 6 | 202 | |
| 7 | Tolerability and weight loss effects of liraglutide in obese adults: a 104-week randomised trial | 0 |
| 8 | Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial | 1 |
| 9 | Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial | 1 |
| 10 | 16 | |
| 11 | Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA (1c)>= 8%) on monotherapy with metformin or sulfonylureas | 1 |
| 12 | 20 | |
| 13 | 2003 William J. Stickel Silver Award. Skin temperatures as a one-time screening tool do not predict future diabetic foot complications | 2 |
| 14 | Sibutramine trial in obesity reduction and maintenance (STORM) | 2 |
| 15 | ASO consensus statement on obesity. UK Association for the Study of Obesity. | 10 |
| 16 | Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom. | 18 |
| 17 | 27 | |
| 18 | PLASMA AMINO-ACID RESPONSES TO CARBOHYDRATE INGESTION IN OBESITY | 1 |
| 19 | DEXTROFENFLURAMINE IN THE TREATMENT OF REFRACTORY OBESITY | 16 |
| 20 | 8 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.